Introduction
The p53 tumor suppressor gene encodes a nuclear transcription factor and is mutated or lost in a majority of human cancers (Donehower and Bradley, 1993; Oren, 1992) . Analysis of its crystal structure reveals that mutations in the p53 gene are most often found in the DNA-binding domain of the protein (Cho et al., 1994) , abrogating its ability to transactivate its target genes (Prives, 1994 ). p53 appears to control the cell cycle by arresting cells in late G1 via the activation of downstream target genes such as p21 WAF1/Cip1 , whose product is an inhibitor of cyclin-dependent kinases (elDeiry et al., 1993) . In addition, p53 has been shown to mediate apoptosis in many cell types through the transcriptional activation or repression of genes like bax or bcl-2, respectively (Miyashita et al., 1994; Miyashita and Reed, 1995; Oren, 1994) . p53-mediated G1-arrest or apoptosis ensue in response to DNA damage-induced strand breaks and the concomitant stabilization of the wild-type p53 protein. Overexpression of wild-type p53 by the transduction of exogenous wtp53 into p53 neg and some p53 mut cell lines may also cause G1 arrest or apoptosis of such cells (Baker et al., 1990; Ramqvist et al., 1993) .
The potential use of wtp53 gene-transduction as an anti-tumor strategy, both in experimental and in clinical settings, is being actively pursued in numerous laboratories. Promising methods of transducing wtp53 into tumor cells use virus-mediated gene-transfer strategies, each of which poses speci®c problems. While some success has been achieved in these endeavors, the eectiveness of retroviral gene transfer into tumor cells is limited by the low numbers of cells that are actually transduced. Much work has been done on attempts to increase the titers of recombinant retroviruses, and methods currently exist which result in the production of viruses with titers 410 6 c.f.u./ml (Pear et al., 1993; Yee et al., 1994) . In the case of retroviruses expressing cell-cycle inhibitors, however, production of high-titer virus in the existing retroviral packaging lines is dicult due to the growth inhibition exerted on the packaging lines themselves by the transgene. Additionally, constructs encoding growthinhibitory genes may be selected against during drugselection of the packaging cells and become deleted or mutated during the propagation of the producer lines.
The pCL retrovirus packaging system, designed by Naviaux and colleagues (Naviaux et al., 1996) , produces a high-titer (*10 7 c.f.u./ml) amphotropic virus following acute co-transfection of late-passage 293 cells with both the packaging construct and a construct encoding a gene of choice. The packaging and the encoding constructs have a hybrid CMV-RU5 5'-LTR and an enhancer-deleted Mo-LTR at the 3'-end. In 293 cells, a line of adenovirus-transformed human kidney cells, these modi®cations ensure E1A driven overexpression of genome-length retroviral RNA which is packaged. Upon reverse transcription, the Mo-LTR of the proviral cDNA is reconstituted and the ensuing virus carries the Mo-LTR at both ends. Hence, the pCL vector system routinely generates non-mutated, hightiter retrovirus encoding negatively-acting genes without lengthy drug selection of producer cells.
Another drawback of retrovirus-mediated transfer of genes such as wtp53 is identifying which cells have been infected, and establishing gene-expression and its duration in infected cells in vitro and in vivo. The green uorescent protein (GFP) has proven to be a good marker for transduced cells. Cells sucessfully transduced with an expression construct encoding GFP uoresce brightly. Fusion of the gene encoding GFP to the wtp53 gene would permit the direct identi®cation of the cells expressing the transduced wtp53 gene and facilitate the study of any resulting phenotype. Here, we describe the construction of a chimeric protein (wtp53GFP) consisting of the wtp53 tumor suppressor gene and a highly¯uorescent mutant of GFP that retains all of the properties of wtp53 while¯uorescing brightly in cells when assayed by¯ow cytometric analysis or by¯uorescence microscopy. When used in conjunction with the pCL retroviral system, the wtp53GFP fusion protein provides an eective method for studying the consequences of wtp53 gene expression on infected cells, both in vitro and in vivo.
Results

wtp53GFP retroviral constructs and virus production
To facilitate the study of the eects of retrovirusmeditated transfer of p53 on cells, the p53 protein was tagged in a manner that would allow ready detection, yet would not aect the normal properties of the protein. This was accomplished by fusing the wild-type human p53 gene with a highly¯uorescent mutant of the A. victoria green¯uorescent protein (cycle3 GFP) (Crameri et al., 1996) . Cycle3 GFP has been optimized for codon usage by eukaryotic cells and contains three mutations which convert hydrophobic residues to hydrophilic ones (F100S, M154T and V164A). These changes result in a readily expressed protein with increased solubility in eukaryotic cells. Additionally, the cycle3 mutant-GFP¯uoresces 46-times more brightly than wild-type GFP at 520 nm as determined by FACS analysis of transduced Chinese hamster ovary cells (Crameri et al., 1996) .
The wtp53GFP fusion protein was constructed by cloning the human wtp53 cDNA into the Alpha+GFP cycle3 vector (Maxygen) in a manner that deleted the stop codon of p53 and linked GFP to its carboxyterminus with the addition of codons for an alanine residue and an arginine residue between the two genes ( Figure 1a ). The wtp53GFP cDNA was then inserted into the polycloning sites of two dierent pCL constructs to create pLTR-wtp53GFP and pCMVwtp53GFP (Figure 1b) . pLTR-wtp53GFP was derived from pCLXSN which allows for the expression of genes under the control of the 5'-LTR. pCMVwtp53GFP is based on the pCLNCX vector which expresses genes from an internal cytomegalovirus (CMV) promoter. Both sets of vectors encode for the neomycin resistance gene, permitting the selection of transduced cells with G418. Control constructs were similarly made using GFP or wild-type p53 alone (pLTR-GFP and pLTR-wtp53, as well as pCMV-GFP and pCMV-wtp53). Infectious retrovirus was produced from these vectors as described in the methods section. Viral supernatants were titered on Balb/c 3T3 cells using G418 selection. Viral titers 410 6 c.f.u./ml have been routinely achieved from all vectors, often with titers greater than 10 7 c.f.u./ml (data not shown). The¯uorescent nature of the wtp53GFP fusion protein was con®rmed by transfecting 293 cells with the retroviral vectors encoding wtp53GFP or GFP. Twenty-four hours after transfection, the cells were analysed by a¯uorescence activated cell scanner (FACS) for¯uorescence. Figure 1c Size, antibody recognition and half-life of the wtp53GFP fusion protein Balb/c 3T3 cells infected with retroviruses encoding the wtp53GFP fusion protein or wtp53 were metabolically labeled and lysates immunoprecipitated. On acrylamide gels, the wtp53GFP fusion protein had a size of approximately 80 kDa. The wtp53GFP fusion protein is recognized by antibodies to p53 and by a polyclonal anti-GFP antibody (Figure 2 ). Of the anti-p53 antibodies tested, the following bind wtp53GFP: mAb 421 (data not shown), which binds wild-type and mutant p53 from several species and binds to p53 at its C-terminus; mAb 1620, which binds p53 in the`wildtype' conformation; and mAb DO1, which recognizes a N-terminal epitope of human p53. Monoclonal antibody 240, which binds speci®cally to p53 in the`mutant' conformation, does not recognize the wtp53GFP protein. The speci®city of the 80 kDa band was con®rmed by performing a sequential immunoprecipitation of the protein with mAb 1620 followed by an immunoblot with the anti-GFP antibody (data not shown). Active wild-type p53 forms homo-dimers and tetramers in cells . As shown in Figure  2 , lanes 9 and 10, wtp53GFP is capable of forming complexes with other wild-type p53 molecules: both the antibody to GFP and the DO-1 antibody, which is speci®c for human p53, co-immunoprecipitate the endogenous murine p53 protein and the exogenous wtp53GFP from infected Balb/c 3T3 cells (compare the murine p53 band in lanes 4 and 9 and in lanes 5 and 10, Figure 2 , respectively).
Balb/c 3T3 cells infected with CMV-wtp53GFP virus were also used to establish the half-life of the wtp53GFP fusion protein. In pulse-chase experiments, the half-life of wtp53GFP was determined to be approximately 40 min, with complete loss of 35 Slabeled protein following 90 min of cell growth in non-labeled medium (data not shown). Cells infected with virus encoding wild-type p53 (human) served as a control. In Balb/c 3T3 cells the fusion protein had the same half-life as that of the exogenous human wtp53, and as the endogenous murine wtp53 protein. This result is consistent with the reported half-life of wtp53 in many non-transformed cell types (Mercer and Baserga, 1985; Oren et al., 1981) .
wtp53GFP retains the transcriptional properties of wildtype p53
Other investigators have produced fusion proteins using one of the available variant forms of GFP, without the loss of functional activity of the proteins in question (Wang et al., 1996; Wang and Hazelrigg, 1994) . Nonetheless, it was important to con®rm that the addition of GFP to the C-terminus of p53 would not aect the wild-type properties of p53. These properties include the ability of wtp53GFP to bind and transcriptionally activate a promoter containing a wtp53-binding site.
A widely-used test for wtp53 transcriptional activity employs the PG13-CAT reporter assay. The PG13-CAT construct contains thirteen copies of a p53-binding site located upstream of the polyomavirus early promoter and the chloramphenicol acetyltransferase gene (Kern et al., 1992) . To assess the ability of the wtp53GFP protein to transactivate the PG13 motif, and to compare this activity to that of wtp53, pCMV-wtp53GFP or pCMV-wtp53 plasmid DNA was co-transfected with the PG13-CAT vector into BHK cells. pCLNCX and pCMV-GFP constructs were used as additional controls to determine any contribution to transactivation by the vector or GFP, respectively. In three separate experiments, the transcriptional activity of wtp53GFP was 96% of that obtained from wtp53 along (Figure 3 ). pCLNCX and GFP each had transcriptional activity that was 3% of that displayed by wtp53, while background activity from the PG13-CAT sample was 2.5% of that of wtp53. These results indicate that the fusion of the GFP protein sequence to the C-terminal end of wtp53 has very little, if any, eect on its ability to transcriptionally activate a wtp53-responsive element.
Suppression of tumor-cell growth by the wtp53GFP fusion protein
To ascertain whether wtp53GFP was able to function as a tumor suppressor, several human glioblastoma multiforme (GBM) cell lines with diering states of endogenous p53 were infected with pCLNCX, CMV-GFP, CMV-wtp53GFP or CMV-wtp53 viruses, and their response in a colony-forming assay was determined. The status of p53 in the cell lines tested is as follows: U87 expresses wild-type p53; HS683 and SF126 lack p53 expression; and the cell lines D384 and U251 both contain mutant forms of p53 (M Haas, unpublished data). Figure 4 shows that infection of the cells with virus encoding wtp53GFP suppresses colony formation by all GBM lines tested at a level equivalent to wtp53 alone. This suppression occurs irrespective of the endogenous form of p53 in each line. In most cases, the number of colonies formed by wtp53GFP or wtp53-infected cells was less than 4% of that for the controls.
When visualized by¯uorescent microscopy, cells expressing the GFP protein had a bright green uorescence over the entire cell, with greater intensity seen in the nucleus (Figure 5a ). The green¯uorescence in cells expressing the wtp53GFP fusion protein was present only in the nucleus, which is the normal subcellular locale of the wtp53 protein (Figure 5b ). Infected cells were also analysed by FACS both 24 h post infection and following G418 selection of the infected cells. In the case of HS683, 30% of the CMV-GFP-infected cells and 36% of the CMV-wtp53GFP infected cells were positive for GFP¯uorescence 24 h after infection. Upon selection with G418, 100% of the CMV-GFP-infected cells were¯uorescent. However, following G418 selection, only 28% of the CMVwtp53GFP-infected cells maintained¯uorescence, consistent with the strong negative eect of wtp53 expression on the proliferation of the GBM cells (data not shown).
Microscopic observation of the wtp53-and wtp53GFP-infected GBM cells also revealed that many single cells that did not form colonies had morphologies distinct from that of the parental cell lines, as well as from the pCLNCX-and GFP-infected cells. The morphology of some cells was characteristic of senescent cells in that they were very large in size and quite¯at. Other cells acquired the morphology of dierentiated neuronal cells. Both of these cell types stained blue when assayed for senescence-associated bgalactosidase activity (Dimri et al., 1995) , (Figure 5e and f). Additionally, many of these cells contained perinuclear lipofuscin granules as is seen in senescent cells (data not shown). The parental and controlinfected cells displayed neither of these properties. Cells present in the colonies formed by wtp53-and wtp53GFP-transduced cells had morphologies identical to that of the parental line or the control-infected populations (data not shown). Analysis of these colonies by¯uorescent microscopy showed that only a fraction of the colonies were positive for wtp53GFP. These results are similar to those obtained by FACS analysis of wtp53GFP-infected HS683 cells after G418 selection.
Discussion
There is no question about the important contribution of p53 toward maintaining genome integrity and, thereby, toward the inhibition of tumorigenic conversion of mammalian cells. While many of the functions of p53 have been elucidated, there are others which are not yet completely understood. The wtp53GFP fusion protein described herein greatly facilitates the identification of cells that have been successfully transduced with wtp53. In this report, wtp53GFP has been thoroughly characterized and shown to retain the structural and functional properties of the wild-type protein: The wtp53GFP fusion protein is recognized by a panel of antibodies that bind wild-type p53, and not by an antibody that is speci®c for mutant p53; The wtp53GFP fusion protein is capable of complexing with other p53 molecules and has a half-life comparable to the wild-type protein. When tested for its ability to transactivate a wtp53-responsive element, the wtp53GFP fusion protein performed at a level nearly identical to that of wtp53 alone. Additionally, GBM The potential uses of the wtp53GFP fusion protein are vast. Our work described here employs the pCL vector system, which allows for the production of hightiter retroviruses encoding negative-growth regulating genes without the need for drug selection. When used in conjunction with wtp53GFP, this system permits the ecient transduction of cells with wtp53GFP and the ready identi®cation of these cells via the GFP moiety of the fusion protein. This makes it possible to quantitate the number of cells infected following exposure to virus, to obtain pure populations of transduced cells on a¯uorescence activated cell sorter and to determine the longevity of p53 expression in cells transduced with wtp53GFP. In animal models for retrovirus-mediated transfer of p53 as a means of antitumor therapy, wtp53GFP enables the researcher to identify which cells are being infected, to determine the duration of gene expression in vivo and to establish if the proliferating tumor cells still produce wtp53GFP.
Other applications of wtp53GFP may not call for retrovirus-mediated gene transfer. For example, the wtp53GFP fusion protein should be useful in studying the transport of p53 from the cytoplasm to the nucleus of a cell in response to speci®c stimuli. Since it is possible to visualize GFP in live cells, these types of studies can be performed in real time. Additionally, mixtures of cells either expressing wtp53GFP or harboring a mutant or deleted allele could be tested for their resistance to various chemotherapeutic agents. Similar enrichment studies have been done using GFP to mark speci®c cell populations (Fink et al., 1997) . In conclusion, the wtp53GFP fusion protein described here is a powerful tool for marking, sorting or characterizing cells transduced with the wtp53 gene and for following expression of the transgene in vitro and in vivo.
Materials and methods
Cells and cell culture
293, a human embryonic kidney cell line (Graham and Eb, 1973) , Balb/c3T3, and BHK cells were maintained in Dulbecco-Vogt modi®ed Eagle's medium (DMEM, Sigma) with the addition of 10% bovine calf serum (HyClone), 100 mg/ml kanamycin sulfate (Gibco BRL) and 5 mg/ml gentamicin sulfate (Elkins-Sinn, Inc.). D384, HS683, SF126, U87 and U251 human glioblastoma cell lines (derived from human grade III and IV gliomas) were grown under the same conditions with the addition of 0.2 units of pork insulin per ml of medium. These cells lines were gifts from Drs CH Langeveld and JJ Heimans, Vrije Universiteit, Amsterdam, The Netherlands.
Retroviral vectors and virus production
The wtp53GFP fusion protein was made by amplifying the human wild-type p53 cDNA with a 5' primer that introduced an EcoRI restriction site 264 bp upstream of the start codon and a 3' primer that replaced the stop codon with a KpnI site. The primer sequences were (5' primer) 5'-GAGAATTCCGGTGGTGGTGCAAATCAA and (3' primer) 5'-CTGGTACCGTCTGAGTCAGGCCCTTCT. Ampli®cation was performed under the following conditions: 938C, 5 min; 30 times (938C, 1 min; 608C, 1 min; 728C, 1 min) and 728C, 5 min. The resulting product was gel puri®ed and cloned into the BlueScriptII vector (Stratagene) that had been digested with EcoRV and had a single thymidine added to the 3' ends by incubating with 10 mM dTTP and Taq DNA Polymerase (Gibco BRL) for 2 h at 758C to produce the pBSp53E/K vector. The p53 fragment was removed from pBSp53E/K by digesting with KpnI (Gibco BRL), incubating with T4 DNA polymerase (Gibco BRL) and 10 mM dNTPs for 20 min at 128C to remove 3' overhangs and digesting with SmaI. The p53 fragment was ligated to the Alpha+GFPC3 vector (Maxigen) that had been linearized with XbaI and incubated with the DNA polymerase large fragment (Klenow) to create blunt ends. Insertion of p53 in the correct orientation produced the Alpha+wtp53GFP vector. The pLTR-wtp53GFP vector was produced by removing the wtp53GFP fragment from Alpha+wtp53GFP with EcoRI and inserting it into the EcoRI site in pCLXSN. pCMV-wtp53GFP was made by digesting Alpha+wtp53GFP with XbaI, incubating with Klenow to create blunt ends and digesting with BspDI to remove wtp53GFP. The wtp53GFP fragment was cloned into pCLNCX vector that had been digested with HindIII, incubated with Klenow to create blunt ends and digested with BspDI. pLTR-GFP was made by digesting Alpha+wtp53(rev)GFP with EcoRI to remove the GFP fragment. The GFP fragment was cloned into the EcoRI site in pCLXSN. pCMV-GFP was constructed by digesting Alpha+GFP with XbaI, creating blunt ends with Klenow and digesting with BspDI. The 746 bp fragment was inserted in pCLNCX that had been digested with HindIII, incubated with Klenow to create blunt ends and digested with BspDI. To create the pLTR-wtp53 vector, the human wtp53 cDNA was removed from pLp53RNL (Cheng et al., 1992) by digesting with BamHI and ligating the 2.1 kb fragment to pCLXSN that had been linearized by digesting with BamHI. pCMV-wtp53 was made by digesting pLp53RNL with BamHI and creating blunt ends with Klenow. The p53 fragment was inserted into the pCLNCX vector that had been digested with HindIII and incubated with Klenow to create blunt ends.
pCL retroviral-vectors and pCLAmpho packaging-vector were cotransfected into late-passage 293 cells as described (Naviaux et al., 1996) . Viral supernatants were harvested 24 and 48 h after transfection. Viral titers were determined by limiting dilution of virus on Balb/c3T3 cells in the presence of 8 mg/ml polybrene (Sigma). Colonies were counted after 10 days of selection with 300 mg/ml G418 (Gibco BRL).
FACS analysis
Adherent cells were trypsinized and washed once with PBS. Cells were resuspended in PBS and immediately subjected to FACS analysis on a Becton Dickinson FACScan using an Argon ion laser tuned to 488 nm to identify GFP positive cells. Fluorescence was observed with a 515/545 bandpass ®lter.
Immunoprecipitation
Balb/c3T3 cells were infected with pCLNCX, CMVwtp53GFP or CMV-p53 viruses in the presence of 8 mg/ ml Polybrene, and the neomycin-resistant cells were selected with 300 mg/ml G418. 5610 6 cells per antibody were incubated for 1 hr in met 7 /cys 7 DME medium, followed by labeling with 100 mCi/ml 35 S-methionine/ cysteine (translabel, ICN) for 4 h. Labeled cells were trypsinized, washed twice with PBS and lysed for 15 min on ice in 250 mM NaCl, 50 mM HEPES (pH 7), 0.1% NP-40, 1% Aprotinin, 0.1 mM EDTA and 500 mM PMSF. Cell lysates were cleared by centrifugation at 100 000 g for 30 min and the supernatants were incubated with the appropriate antibody overnight at 48C. Immune complexes were collected on immobilized recombinant protein A (Repligen), washed three times with lysis buer, once with PBS, boiled for 2 min in sample buer and electrophoresed on a 10% SDS-polyacrylamide gel. Samples were visualized by autoradiography.
Antibodies
Monoclonal antibody PAb 421 (Harlow et al., 1981) recognizes both human and murine p53. Monoclonal antibody PAb 1620 (Milner et al., 1987) recognizes wildtype p53 and monoclonal antibody PAb 240 (Gannon et al., 1990) detects most mutant p53 proteins. MAb DO-1 recognizes human but not murine p53 (Vojtesek et al., 1992) . Anti-GFP is a polyclonal antibody against GFP and was kindly provided by Charles Zucker. PAb 419 recognizes SV40 large T antigen and was used as a nonspec®c control (Harlow et al., 1981) .
Half-life determination p53 was immunoprecipitated from infected BalbC/3T3 cells as described, except cells were labeled with 35 S-translabel for 30 min followed by incubation in DME medium (Sigma) plus 10% calf serum for 30 min to 6 h. Monoclonal antibody PAb 1620 was used to precipitate wtp53GFP and wtp53 and PAb 419 was used as a nonspeci®c control. Bands were quantitated using a Phosphorlmager (Molecular Dynamics).
PG13-CAT assays
BHK cells were cotransfected using the calcium phosphate method (Chen and Okayama, 1988) with the appropriate vector and the PG13-CAT construct. Thirty hours later, cells were lysed and 25 mg of protein was incubated with 14 Cchloramphenicol and acetyl CoA. Samples were run on TLC to separate acetylated from unacetylated species. Percent acetylation was determined by scintillation counting.
GBM colony assays
Glioblastoma cell lines were infected with the indicated viruses three times over a 12 h period in the presence of polybrene (8 mg/ml) with a ®nal m.o.i. of 2. Twenty-four hours later, dilutions of cells were plated in duplicate. G418 (800 mg/ml) selection began at day 3 and continued for 9 days, at which time cells were ®xed with 100% methanol and stained with Geimsa for enumeration of colonies.
GFP slides
Infected HS683 cells were grown on glass slides and selected with G418. After 10 days of selection, the slides were washed with PBS, ®xed in fresh 4% paraformaldehyde for 10 min at RT and rinsed in distilled H 2 O. Indicated samples were counterstained with 0.01% Evans Blue for 15 min and rinsed in distilled H 2 O. Coverslips were mounted with glycerol-PBS (1 : 1).
Senescence-associated b-gal assay
After G418 selection, infected HS683 cells were ®xed in 2% formaldehyde/0.2% glutaraldehyde, washed with PBS, and incubated at 378C with fresh senescence-associated b-gal stain solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside (X-gal, International Biotechnologies, Inc.), 40 mM citric acid/sodium phosphate, pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl and 2 mM MgCl 2 ) for 48 h.
